Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,

#3838 Subgroup analysis of ORR and PFS of the SEQTOR study (GETNE 1206) – Everolimus followed by Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs

Introduction: Previous global results of ORR and PFS1 have been presented. The best treatment (Tx) sequence between STZ-5FU and everolimus (EVE) in patients (pts) with advanced and progressive panNETs is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R,

Keywords: panNET, everolimus, STZ-5FU,

#3550 Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Introduction: STZ-5FU and everolimus are frontline options for systemic treatment in patients with advanced and progressive pancreatic neuroendocrine tumors (panNETs). Switch between both upon progression is a common strategy, but the best sequence is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Vestermark L, Teulé A, Garcia-Carbonero R,

Keywords: pNET, everolimus, streptozotocin, 5FU, randomized trial,